证券代码：688176 证券简称：亚虹医药 公告编号：2026-009 一、非独立董事辞任情况 （一）辞任的基本情况 | 姓名 | 离任 | 离任时间 | | 原定任期到期 | 离任原因 | 是否继续在上 市公司及其控 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 职务 | | | 日 | | | | | | | | | | | 股子公司任职 | 公开承诺 | | 李显显 | 董事 | 年 2026 | 3 | 第二届董事会 | 因个人原因， | 否 | 否 | | | | 月 27 | 日 | 届满之日 | 申请辞任 | | | （二）辞任对公司的影响 根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》等 法律法规以及《公司章程》的规定，李显显先生的离任未导致公司董事会成员人 数低于法定最低人数，不会影响公司董事会的正常运行，李显显先生的辞任报告 自送达公司董事会之日起生效。截至本公告披露日，李显显先生未持有公司股份。 李显显先生已确认不存在应履行而未履行的公开承诺事项，亦无任何事项需提请 公司股东注 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of products with price leadership amid rising costs in the supply chain due to geopolitical tensions and policy changes affecting raw material prices [2] - The report highlights the significant price increases in pharmaceutical raw materials, particularly vitamins and amino acids, which have seen price increases of 40.54% and 84.66% respectively since the beginning of the year [2] - The report notes the approval of China's first invasive brain-machine interface, marking a significant milestone in the medical device sector [5] - The report indicates a strong trend in China's innovative pharmaceuticals going global, with a notable increase in licensing-out transactions [6] Summary by Sections 1. Supply Chain Dynamics - The report discusses the impact of rising prices in upstream chemical products on pharmaceutical raw materials, stressing that the ability to pass on these costs is crucial for maintaining profitability [2] - It mentions that 90% of monitored products have seen price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] 2. Market Trends in Disposable Gloves - The report details the price increases in disposable nitrile gloves and PVC gloves due to rising costs of raw materials like butadiene and acrylonitrile, which have increased by 84.43% and 47.30% respectively [3] - It notes that the domestic utilization rate for nitrile gloves has improved, and export prices have been rising since late 2025 [3] 3. Regulatory Environment - The report highlights the impact of dual-use item management on the pricing of key materials, creating significant price disparities between domestic and international markets [4] - It suggests that stricter controls on resources like rare earths could enhance the competitive advantage of domestic medical products [4] 4. Innovations in Medical Devices - The report discusses the approval of the brain-machine interface by the National Medical Products Administration, which is expected to open new market opportunities [5] - It outlines the potential for significant market growth in this area, given the high number of spinal cord injury patients in China [5] 5. International Expansion of Chinese Pharmaceuticals - The report notes that there have been 39 licensing-out transactions in the innovative drug sector, with upfront payments totaling approximately $2.953 billion [6] - It emphasizes that the trend of Chinese pharmaceuticals going global continues to strengthen, with a focus on small nucleic acid drugs and dual antibodies [7] 6. Stock Recommendations - The report recommends focusing on raw material suppliers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Inco Medical and Blue Sail Medical in the disposable glove sector [8] - It also suggests monitoring companies involved in the invasive brain-machine interface and small nucleic acid drugs, indicating potential for growth in these areas [8]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of price leadership in the pharmaceutical sector, particularly in the context of rising raw material costs due to geopolitical tensions and supply chain disruptions [2] - The report highlights the approval of China's first invasive brain-machine interface, marking a significant milestone in medical technology and potential market opportunities [5] - The report notes a strong trend in China's innovative drug exports, with a significant increase in licensing deals and collaborations, indicating robust growth in the sector [6] Summary by Sections Supply Chain and Pricing Dynamics - The report discusses the impact of macroeconomic changes on supply chains, particularly the price increases in upstream chemical products affecting pharmaceutical raw materials [2] - It mentions that 90% of monitored products saw price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] - Specific raw materials like Vitamin E and methionine have seen price increases of 40.54% and 84.66% respectively since the start of the year [2] Market Trends and Innovations - The report details the rising prices of disposable gloves due to increased costs of upstream materials, with notable price hikes in butadiene and acrylonitrile [3] - It highlights the competitive landscape for disposable gloves, noting that leading companies are leveraging their cost advantages to implement price increases [3] - The report also discusses the potential for domestic medical products to benefit from export controls on dual-use items, enhancing China's competitive edge [4] Regulatory Developments and Market Opportunities - The approval of the brain-machine interface by the National Medical Products Administration is a significant development, with a large potential patient base in China [5] - The report outlines the introduction of new pricing guidelines for invasive brain-machine interfaces, which could facilitate market entry and reimbursement [5] Investment Recommendations - The report recommends focusing on raw material producers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Yingke Medical and Blue Sail Medical in the disposable glove sector [8] - It suggests monitoring companies benefiting from resource management policies, such as Aidi Te, and those involved in the invasive brain-machine interface market, like Meihua Medical [8] - The report also emphasizes the growth potential in the small nucleic acid drug sector, recommending companies like Yuyuan Pharmaceutical and Sunshine Nuohe [8] Company Performance and Forecasts - The report provides earnings forecasts for key companies, indicating a positive outlook for several firms in the pharmaceutical sector, with specific EPS and PE ratios highlighted for investment consideration [9]

Investment Rating - The report maintains a "Buy" investment rating for the company [1] Core Insights - The approval of the core product APL-1702 marks a new stage in the company's development, with significant commercial preparations already in place for its market launch [5] - APL-1702, branded as 希维她®/CEVIRA®, is a pioneering photodynamic therapy product aimed at treating patients with cervical intraepithelial neoplasia (CIN2), addressing a substantial unmet clinical need in non-invasive treatment options [6] - The company is actively pursuing international market opportunities, having received acceptance from the European Medicines Agency and reached an agreement with the FDA on the clinical design for U.S. market entry [5] Financial Performance - The company forecasts revenues of 277 million yuan in 2025, representing a year-on-year growth of 37.49%, driven by the commercialization of existing products [7] - The net profit attributable to the parent company is projected to be -419 million yuan for 2025, reflecting ongoing high R&D investments and preparations for new product commercialization [8] - Revenue projections for 2025-2027 are 277 million, 501 million, and 803 million yuan respectively, with net profits expected to improve from -419 million to -149 million yuan over the same period [8][10] Market Demand - There is a significant unmet clinical demand for non-invasive treatments for cervical intraepithelial neoplasia, with over 700,000 diagnosed HSIL patients in China, of which approximately 60% are CIN2 cases [6] - The World Health Organization's initiative to eliminate cervical cancer aligns with the company's goals, as China aims for a 90% treatment rate for cervical cancer and precancerous lesions by 2030 [6] Commercialization Strategy - The company is implementing a "Commercialization 2.0" strategy, which has shown effectiveness with continuous growth in generic drug sales [5] - The successful launch of APL-1702 is expected to significantly enhance the company's revenue, alongside the ongoing growth of its generic drug portfolio [8]

Investment Rating - The report maintains a "Buy" investment rating for the company [1] Core Insights - The approval of the core product APL-1702 marks a new stage in the company's development, with significant commercial preparations already in place for its market launch [5] - APL-1702, branded as 希维她®/CEVIRA®, is a pioneering photodynamic therapy product aimed at treating patients with cervical intraepithelial neoplasia (CIN2), addressing a substantial unmet clinical need for non-invasive treatment options [6] - The company is actively pursuing international market opportunities, having received acceptance from the European Medicines Agency and reached an agreement with the FDA on the clinical design for U.S. market entry [5] Summary by Sections Market Performance - The company's stock price is currently at 16.91 yuan, with a total market capitalization of 9.7 billion yuan and a 52-week price range of 7.22 to 17.66 yuan [1] Investment Highlights - The company reported a revenue of 277 million yuan for 2025, reflecting a year-on-year growth of 37.49%, driven by the commercialization of its products [7] - The net profit attributable to the parent company is projected to be -419 million yuan for 2025, primarily due to ongoing R&D investments and preparations for new product launches [7] - Revenue forecasts for 2025-2027 are 277 million, 501 million, and 803 million yuan respectively, with net profits expected to improve from -419 million to -149 million yuan over the same period [8] Financial Projections - The report predicts a significant increase in revenue growth rates, with 2025 expected to see a 37.5% increase, followed by 80.8% in 2026 and 60.3% in 2027 [10] - The earnings per share (EPS) are projected to improve from -0.73 yuan in 2025 to -0.26 yuan in 2027, indicating a potential turnaround in profitability as the core product gains market traction [8]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [3] Core Insights - The strategic position of the biopharmaceutical industry has been elevated, with innovative drugs, medical devices, and elderly care services expected to face structural opportunities in the medium to long term [2][36] - The 2026 government work report has classified the biopharmaceutical industry as a pillar industry alongside integrated circuits and aerospace, emphasizing its importance in the national economy [33][36] - There is a shift towards "full-chain support" for innovative drug development, with policies moving from macro-level support to practical payment systems, indicating a new era of diversified payment methods for innovative drugs [37][38] Summary by Sections Market Review - The biopharmaceutical index fell by 2.78% this week, underperforming the CSI 300 index by 1.71 percentage points, ranking 17th in industry performance [14] - Year-to-date, the biopharmaceutical index has increased by 0.1%, also underperforming the CSI 300 index by 0.56 percentage points, ranking 24th [14] Individual Stock Performance - In the A-share market, among 480 biopharmaceutical stocks, 75 stocks rose, accounting for 15.63%. The top five gainers were: - Yahui Pharmaceutical (+38.11%) - Zhejiang Medicine (+12.83%) - Zhongyuan Xiehe (+12.69%) - Duorui Pharmaceutical (+12.55%) - Jiuan Medical (+10.48%) [27][28] - In the Hong Kong market, 116 biopharmaceutical stocks saw 23 rise, making up 19.83%. The top ten gainers included: - Yaojie Ankang-B (+33.53%) - Deqi Pharmaceutical-B (+19.57%) - Baize Medical (+12.87%) [30][31] Industry News and Policies - The biopharmaceutical industry has been explicitly included in the national "emerging pillar industries" category, with policies aimed at enhancing multi-level medical insurance systems and promoting the development of innovative drugs and medical devices [33] - The government is encouraging commercial health insurance to cover more reasonable medical expenses outside the basic medical insurance directory, which is expected to boost investment in innovative drug development [38] Weekly Insights - The report suggests focusing on the long-term development of the biopharmaceutical industry, particularly on innovative drug and device companies that are pioneering in their fields, as well as the related industries in the silver economy [39]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a focus on companies with validated platforms and effective innovative drugs, indicating a positive outlook for the sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.78% from March 2 to March 6, underperforming compared to the Wind All A index (-2.3%) and the CSI 300 index (-1.07%). The only sub-sector that saw an increase was in vitro diagnostics (0.18%), while medical R&D outsourcing (-4.99%), medical devices (-4.62%), and vaccines (-3.81%) led the declines [2][7]. - Recent business development (BD) activities in the domestic innovative drug sector are vibrant, with significant deals announced, including China National Pharmaceutical Group's exclusive licensing agreement with Sanofi for the drug rovalpituzumab tesirine, valued at $1.53 billion, and a similar agreement between Deqi Pharmaceutical and UCB for ATG-201, valued at over $1.18 billion. These transactions reflect a strategic shift towards a multi-layered outbound strategy for Chinese pharmaceutical companies [2][10]. - The report emphasizes the competitive advantages of domestic innovative drugs in areas such as bispecific antibodies and antibody-drug conjugates (ADCs), suggesting that companies with validated platforms are likely to continue generating new pipeline candidates [2]. Market Weekly Review - The pharmaceutical and biotechnology sector followed the broader market trend and declined by 2.78% during the week of March 2 to March 6, with the in vitro diagnostics sector being the only one to gain [7][8]. - Notable stock performances included Yahu Pharmaceutical (up 38.1%), Zhejiang Pharmaceutical (up 12.8%), and Zhongyuan Xiehe (up 12.7%), while Tianzhihang-U (down 14.8%), Furui Medical (down 13.1%), and Haoyuan Pharmaceutical (down 12.3%) faced significant losses [10].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a focus on companies with validated platforms and effective innovative drugs, indicating a positive outlook for certain segments within the industry [2]. Core Insights - The pharmaceutical and biotechnology sectors are experiencing a shift towards a multi-layered overseas strategy, with Chinese companies increasingly recognized by global multinational corporations (MNCs) for their research capabilities and technology platforms [2]. - Recent significant business development (BD) deals include China National Pharmaceutical Group's exclusive licensing agreement for the drug Rovabatinib worth $1.53 billion and the collaboration between Deqi Pharmaceutical and UCB for the CD19/CD3 bispecific T cell engager ATG-201, valued at over $1.18 billion [2][10]. - The report highlights the performance of the in vitro diagnostics sector, which was the only sub-sector to see a gain of 0.18%, while other segments like medical device and vaccine sectors faced declines [7][8]. Market Weekly Review - The pharmaceutical and biotechnology sector fell by 2.78% from March 2 to March 6, underperforming the Wind All A index (-2.3%) and the CSI 300 index (-1.07%) [7]. - Notable stock performances included Yahui Pharmaceutical (+38.1%), Zhejiang Pharmaceutical (+12.8%), and Zhongyuan Xiehe (+12.7%) as top gainers, while Tianzhihang-U (-14.8%), Furui Medical (-13.1%), and Haoyuan Pharmaceutical (-12.3%) were the biggest losers [10]. Industry News and Key Company Announcements - On March 6, Xianweida Biopharmaceutical and Pfizer announced the approval of a new indication for their GLP-1 receptor agonist, Enoglutide, for long-term weight management in adults [10]. - China National Pharmaceutical Group's licensing agreement for Rovabatinib includes a $135 million upfront payment and potential milestone payments based on sales performance [10]. - Deqi Pharmaceutical's agreement with UCB for ATG-201 includes an upfront payment of $80 million and potential milestone payments exceeding $1.1 billion [10]. - Wanbangde reported a significant increase in net profit for Q1 2026, reaching 165 million yuan, a year-on-year growth of 985.4% [11].

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][53]. Core Viewpoints - The report emphasizes the strong logic behind the innovative drug industry, suggesting that the stock prices have adjusted sufficiently, making current investments relatively cost-effective. It recommends focusing on stocks with high or certain returns, particularly those expected to perform well in Q1 [5][42]. - The report highlights the rapid growth of balloon-expandable valves (BEV) in TAVR procedures, with a projected increase in the number of procedures in China, reaching over 18,000 by 2025, representing an 8.1% year-on-year growth. The proportion of BEV usage is expected to rise significantly [8][16]. - The report outlines a dual investment framework focusing on "technology innovation leadership" and "performance/valuation recovery" for the year [23][43]. Summary by Sections 1. TAVR Procedure Growth - The number of TAVR procedures in mainland China is expected to exceed 18,000 by 2025, with a year-on-year growth of 8.1%. The proportion of balloon-expandable valves is projected to increase from 7.5% in 2024 to 13% in 2025 [8][16]. 2. Industry Performance Analysis - From March 2 to March 6, the pharmaceutical index fell by 2.78%, underperforming the CSI 300 index by 1.71%. Despite this, innovative drugs showed a significant rebound, with stocks like Yahu Medicine rising over 38% [5][23]. - The report lists several stocks to watch, including innovative drug companies and those with stable growth or potential for performance reversal [5][42]. 3. Investment Recommendations - The report suggests focusing on innovative drugs, AI medical technology, and surgical robots as key areas for investment in 2026. Specific companies highlighted include Heng Rui Medicine, Xin Li Tai, and Bai Ren Medical [5][42][45]. - It also emphasizes the importance of the aging population and outpatient consumption as growth drivers, recommending companies like Kun Yao Group and Yu Yao Medical [45]. 4. Market Trends and Valuation - The overall PE valuation for the pharmaceutical sector is 36.18x, indicating that the sector remains at a relatively low historical valuation. The report notes that various sub-sectors have differing valuation levels, with some being relatively high [31][42].

Investment Rating - The report maintains an "Increase" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector has experienced a decline of 2.78% this week, ranking 17th out of 31 sectors, while it has seen a slight increase of 0.1% year-to-date, ranking 24th out of 31 [9] - The 2026 government work report emphasizes the importance of the biopharmaceutical industry, categorizing it as a "new pillar industry," which indicates a strategic upgrade in its significance for economic growth and industrial upgrading [10][11] - The inclusion of brain-computer interfaces in the government work report marks a significant policy shift, enhancing market focus on related fields such as neural regulation and rehabilitation robotics [11] Company Dynamics - China Biopharmaceutical has entered an exclusive licensing agreement with Sanofi for the innovative drug Roflumilast, potentially earning up to $1.53 billion, including an upfront payment of $135 million [12] - Deking Pharmaceuticals has secured a global exclusive licensing agreement for ATG-201 with UCB, which includes an upfront payment of $80 million and potential milestone payments totaling approximately $1.1 billion [13] - East China Pharmaceutical has received approval to conduct clinical trials for DR30206, a fusion protein targeting multiple pathways for non-small cell lung cancer [14] - Yahui Pharmaceutical has achieved a commercial breakthrough with the approval of APL-1702 for treating cervical intraepithelial neoplasia [15] Investment Focus - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector as key investment opportunities [4][16]